Paul Zuidgeest

Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease

Abstract Background Traditional metastatic burden classifications in metastatic hormone-sensitive prostate cancer (mHSPC) rely on conventional imaging using CHAARTED criteria. As PSMA PET/CT is increasingly used for staging, revised definitions of low-volume (LVD) and high-volume...